What Is Intratumoral Immunotherapy and How Does It Work?

Turning the Tumor Against Itself

Cancer immunotherapy has transformed oncology over the past decade—but its most powerful forms often come with a serious drawback: when immune-activating drugs flood the entire bloodstream, they can trigger dangerous inflammation anywhere in the body. A newer strategy sidesteps that problem by delivering treatment directly into the tumor. This approach, called intratumoral immunotherapy, is attracting intense research interest and producing some striking early results.

How It Works

The core idea is deceptively simple: instead of injecting a drug into a vein and hoping it reaches the cancer, clinicians guide a needle into the tumor itself and deposit the therapeutic agent right at the target. This allows far higher local drug concentrations than would be safe to give systemically, while the rest of the body is largely spared.

Once inside the tumor, the injected agent sets off a cascade. It disrupts the tumor's immunosuppressive microenvironment—the chemical and cellular shield that cancer builds around itself to hide from immune attack. Immune cells called dendritic cells are activated; they ingest tumor debris and present it as foreign to T cells, effectively teaching the immune system to recognize that specific cancer as an enemy.

Researchers describe this as creating an in situ vaccine: rather than manufacturing and injecting a vaccine outside the body, the therapy uses the tumor's own proteins as the antigen, training the immune system on-site.

The Abscopal Effect: Fighting Cancer Everywhere

The most remarkable feature of intratumoral immunotherapy is what happens beyond the injected tumor. Once activated, tumor-specific T cells circulate through the bloodstream and can attack metastases in distant organs—lesions that were never directly treated. Scientists call this the abscopal effect.

Clinical studies have documented responses in non-injected tumors in patients receiving intratumoral treatment, suggesting the approach can function as a whole-body cancer therapy, not merely a local one. In one phase I trial of an Fc-engineered CD40 agonist antibody injected directly into tumors, 20% of patients with metastatic cancer showed measurable responses, including two complete remissions—impressive figures for a first-in-human study of a heavily pre-treated population.

What Gets Injected?

Several classes of agents are being tested intratumorally:

• Oncolytic viruses — Genetically engineered viruses that infect and kill cancer cells while triggering immune alerts. Talimogene laherparepvec (TVEC), a modified herpes simplex virus, became the first FDA-approved intratumoral therapy in 2015, achieving roughly 11% complete response rates in advanced melanoma.
• TLR and STING agonists — Molecules that mimic bacterial or viral signals, activating innate immune sensors inside the tumor. STING agonists combined with checkpoint inhibitors have produced objective response rates around 24% in early phase trials.
• Checkpoint inhibitors — Drugs like ipilimumab, when injected directly into tumors rather than given intravenously, showed a 50% response rate with only 30% toxicity at six months—compared with over 57% toxicity via the systemic route.
• CD40 agonist antibodies — These activate dendritic cells to supercharge antigen presentation. Previous systemic versions caused severe liver toxicity; intratumoral delivery has allowed dose escalation without those complications.

Why Not Just Give Everything Systemically?

Many of the agents most effective at activating immune cells are too dangerous to deliver throughout the body. Cytokines, for example, can provoke life-threatening inflammatory storms when circulated systemically. Intratumoral delivery lets physicians use potent agents they otherwise could not, because peak drug concentrations remain local while systemic exposure stays low.

There is also a cost and access argument: intratumoral therapies typically require smaller drug quantities and, in some cases, simpler manufacturing pipelines than cell therapies like CAR-T—potentially making them more accessible in resource-limited settings.

Challenges Still to Solve

Intratumoral immunotherapy is not without obstacles. Deep-seated or inaccessible tumors—in the lungs, pancreas, or brain—are difficult to reach with a needle reliably. Tumors also vary greatly in their internal architecture: highly necrotic or fibrotic areas impede drug spread. Biophysical barriers such as high internal fluid pressure can push drugs back out after injection.

Early phase III trials have produced mixed results, partly because injection techniques varied enormously across study sites. Standardizing delivery protocols—needle design, injection volume, lesion selection—is now recognized as essential for consistent outcomes.

The Road Ahead

Researchers increasingly believe that combination strategies hold the most promise: pairing intratumoral therapy with systemic checkpoint inhibitors, chemotherapy, or radiotherapy to maximize the immune response. Several dozen clinical trials are active worldwide, testing combinations in melanoma, breast cancer, liver cancer, and beyond.

The underlying concept—using the tumor as both target and training ground—represents a fundamental shift in how medicine approaches cancer. If the abscopal effect can be reliably triggered and sustained, a single needle injection could one day treat disease spread across an entire body.